Cocrystal Pharma (FRA:8CC) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8CC Cocrystal Pharma Inc FRA:8CC
25 GF Score
Price €0.86
GF Value €2.43
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cocrystal Pharma Net Loan?

Net Loan only applies to banks and insurance companies.

FRA:8CC
25GF Score
Cocrystal Pharma Inc FRA:8CC
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cocrystal Pharma (FRA:8CC) Overvalued in 2026?

Based on GuruFocus' analysis, Cocrystal Pharma stock appears to be undervalued. The current stock price of €0.86 is trading 64.8% below its estimated GF Value™ of €2.43. GuruFocus considers Cocrystal Pharma to be Possible Value Trap.

Key valuation signals for FRA:8CC:

  • Net Loan:
  • GF Value™: €2.43 vs. price of €0.86 (64.8% below fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the FRA:8CC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score

Get the complete analysis for FRA:8CC

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€2.43
GF Value